Oral Biolife wins NIH grant to study non-surgical peri-implantitis treatment

Oral Biolife received an NIH grant through NIDCR to test whether its piezoelectric regenerative platform can help treat peri-implantitis, a condition that causes bone loss around dental implants. The Temple University-led study expands the company’s technology beyond periodontal bone regeneration and could support broader dental and orthopedic uses.

Why it matters: - The NIH award gives Oral Biolife external validation as it expands its regenerative platform beyond periodontal bone regeneration. - Peri-implantitis can lead to progressive bone loss around dental implants and implant failure, creating demand for less invasive treatments. - The study could help establish whether Oral Biolife’s technology has broader value across multiple bone-regeneration indications.

What happened: - Oral Biolife announced that the National Institutes of Health, through the National Institute of Dental and Craniofacial Research, awarded the company a grant to study its technology as a potential non-surgical treatment for peri-implantitis. - The research will be led by Ronaldo Santana, DMD, Professor and Chair of the Department of Periodontology and Oral Implantology at Temple University’s Maurice H. Kornberg School of Dentistry. - Dr. Santana will serve as principal investigator on the NIH-supported program.

The details: - Oral Biolife develops a first-in-class piezoelectric regenerative platform designed to stimulate new bone formation. - The company’s lead human product, Ambrilux™ Dental Gel, is in development for periodontal bone regeneration. - The platform is designed to convert naturally occurring mechanical forces into localized bioelectric signals that activate physiological pathways tied to bone formation. - The peri-implantitis program will test whether that regenerative mechanism can address another dentistry indication marked by progressive bone loss. - Peri-implantitis affects tissues around dental implants and can require surgical intervention under current treatment approaches. - The company’s veterinary product, Restoris™, launched in 2025.

Between the lines: - The NIH funding suggests Oral Biolife is trying to turn a single-disease concept into a broader platform story. - Bringing in a Temple University periodontology and implantology leader adds scientific credibility to the program. - If the platform works in peri-implantitis, Oral Biolife could strengthen its case for use in other dental, craniofacial and orthopedic bone-regeneration settings.

What’s next: - Oral Biolife and Temple University will evaluate the technology in peri-implantitis under the NIH-supported study. - Future development opportunities include additional dental and craniofacial applications, plus orthopedic indications involving bone regeneration. - The company said the work moves it closer to regenerative treatments that could change how patients with bone loss are treated.

The bottom line: - The NIH grant broadens Oral Biolife’s clinical reach and gives the company a new test case for its piezoelectric regenerative platform beyond periodontal disease.